Država: Južnoafriška republika
Jezik: angleščina
Source: South African Health Products Regulatory Authority (SAHPRA)
Stiefel
STIEMYCIN Topical solution SCHEDULING STATUS S4 PROPRIETARY NAME (and dosage form) STIEMYCIN Topical solution COMPOSITION Stiemycin contains per 100 mL : 2g erythromycin base PHARMACOLOGICAL CLASSIFICATION A13.12 Acne preparations. PHARMACOLOGICAL ACTION Erythromycin is a macrolide antibiotic. It interferes with bacterial protein synthesis by binding to the 50S subunit of ribosomes of sensitive organisms. Although the mechanism of action of Stiemycin in reducing inflammatory lesions of acne vulgaris has not been conclusively shown, it is presumably due to its antibiotic action on sensitive bacteria, and in reducing follicular porphyrin fluorescence and free fatty acid levels of skin lipids. INDICATIONS Stiemycin is indicated for the topical treatment of moderate acne vulgaris. CONTRA-INDICATIONS Patients with known hypersensitivity to erythromycin or other macrolide antibiotics or propylene glycol should not use Stiemycin. In the event of irritation, stop using Stiemycin and consult your doctor. WARNING Avoid contact with eyes and other mucous membranes. This product is for external use only. Safety in pregnancy has not been established. DOSAGE AND DIRECTIONS FOR USE Apply Stiemycin, using the applicator on the bottle to the effected area twice daily after washing with soap and water. SIDE-EFFECTS AND SPECIAL PRECAUTIONS Dryness, pruritus, erythema, desquamation and burning sensation have been reported. Concomitant topical acne therapy should be used with caution because a cumulative irritant effect may occur, specially with the use of abrasive agents. The use of topical antimicrobial agents has been associated with the overgrowth of antibiotic-resistant organisms on the skin. Should this occur, administration should be discontinued and appropriate measures taken. KNOWN SYMPTOM Preberite celoten dokument